Last Updated On 3 September 2026, 3:58 PM EDT (Toronto Time)
Health Canada is replacing the patchwork of federal regulations that currently govern prescription drugs containing controlled substances with a single consolidated framework that takes effect on October 1, 2026.
The new Controlled Substances Regulations, published in the Canada Gazette on December 17, 2025, will merge the Narcotic Control Regulations, the Benzodiazepines and Other Targeted Substances Regulations, Parts G and J of the Food and Drug Regulations, and the New Classes of Practitioners Regulations into one modernized set of rules.
6 temporary class exemptions issued under subsection 56(1) of the Controlled Drugs and Substances Act will also be absorbed into the permanent regulatory text.
The transition is designed to be seamless for patients filling prescriptions at Canadian pharmacies, but the regulatory machinery behind those prescriptions is changing in ways that pharmacists, healthcare practitioners, hospitals, licensed dealers, and travellers crossing the border with medication all need to understand before the October 1 deadline.
Table of Contents
What the October 1 Consolidation Replaces
Canada’s controlled substances have been governed by separate regulations organized by drug category since the 1960s.
Narcotics such as morphine, codeine, and fentanyl were regulated under the Narcotic Control Regulations.
Controlled drugs, including certain amphetamines and barbiturates, fell under Part G of the Food and Drug Regulations.
Targeted substances like benzodiazepines operated under the Benzodiazepines and Other Targeted Substances Regulations.
Restricted drugs, including LSD and psilocybin when used in authorized research, were regulated under Part J of the Food and Drug Regulations.
Each framework carried its own licensing procedures, record-keeping obligations, and security requirements, which sometimes conflicted with or duplicated the others.
Beginning October 1, all four categories will be listed in Schedules 1 through 4 of the new Controlled Substances Regulations instead of being scattered across three separate regulatory instruments.
The definition of what qualifies as a controlled substance is not changing.
What is changing is where those substances are listed and the administrative rules that pharmacists and licensed dealers must follow when handling them.
Key Changes for Pharmacists and Practitioners
The most visible shift for pharmacy professionals is the permanent embedding of authorities that have operated on a temporary basis since March 2020.
A pandemic-era class exemption under subsection 56(1) of the CDSA gave pharmacists expanded flexibility to extend, renew, and transfer prescriptions for narcotics, controlled drugs, and targeted substances such as benzodiazepines.
That temporary exemption was extended in 2021 with a final expiry date of September 30, 2026.
On October 1, those same authorities become permanently established under the consolidated regulations.
Pharmacists will continue to be able to extend, renew, and transfer prescriptions for controlled substances under the new permanent rules without any gap in coverage on the transition date.
Therapeutic Substitution Becomes a Permanent Federal Authority
One of the most significant new provisions removes the federal regulatory barrier that currently prevents pharmacists from therapeutically substituting one controlled substance for another, provided the pharmacist is authorized to do so under the laws of the province or territory where they practise.
The Canadian Pharmacists Association has highlighted shortages involving acetaminophen with codeine or oxycodone as an example of situations in which greater pharmacist flexibility can help maintain patient access to treatment.
However, there is an important qualification that patients and pharmacists must understand.
The federal regulation creates the authority, but a pharmacist can only exercise it where their province or territory has also enabled therapeutic substitution within its scope-of-practice rules.
Ontario, for example, has not included therapeutic substitution within the scope of practice for Ontario pharmacists, as explained by the Ontario College of Pharmacists.
Ontario pharmacists can adapt prescriptions for controlled substances, including adjustments to dose, dosage form, regimen, and route of administration, but they cannot swap one controlled substance for a different one.
Provinces and territories that have already authorized therapeutic substitution in their pharmacy legislation will see the new federal authority take effect immediately on October 1.
Expanded Authorities for Pharmacy Technicians
The consolidated regulations also formally authorize pharmacy technicians to independently perform a range of activities involving controlled substances where permitted under provincial or territorial regulation.
These activities include compounding, transferring prescriptions, and on-site destruction of controlled substances.
As with pharmacist authorities, the federal regulation is enabling legislation that requires a matching provincial authorization before a pharmacy technician can carry out these tasks.
New Hospital Framework
The regulations introduce a newly defined category of “persons in charge of a hospital” who will be authorized to permit employees, including pharmacy professionals, to administer, sell, provide, send, deliver, and transport controlled substances.
This framework also incorporates class-exemption permissions for on-site destruction of controlled substances and transfers to licensed dealers for destruction.
Hospital administrators will need to review the new regulatory text to confirm that their internal protocols for handling controlled substances align with the consolidated rules before October 1.
What Changes for Patients Filling Prescriptions
For Canadians who fill prescriptions for controlled substances, the practical impact of the October 1 transition should generally be limited.
No prescription that was valid on September 30 will become invalid on October 1.
The consolidation itself does not newly reclassify existing prescribed controlled substances, and no medications are being removed from the controlled substances list as part of this regulatory reform.
Patients should not experience any disruption when filling prescriptions at their regular pharmacy.
The transition is administrative and structural, not clinical.
However, patients who rely on controlled substances for ongoing treatment should be aware that the permanent establishment of prescription-renewal and prescription-transfer authorities means these accommodations are no longer dependent on a temporary exemption that could theoretically be revoked.
That provides an additional layer of regulatory certainty for Canadians who depend on medications such as opioid painkillers, benzodiazepines, or stimulant medications for conditions like ADHD.
Updated Rules for Travellers Carrying Prescription Medication
One of the most significant consumer-facing changes taking effect October 1 involves Canadians and international travellers carrying prescribed controlled substances across the border.
Under the new regulations, travellers entering or leaving Canada will be permitted to carry up to a 90-day supply of prescribed medication containing a narcotic, controlled drug, or targeted substance, provided the federal requirements are met.
This replaces the 30-day limit that currently applies to narcotics and controlled drugs and aligns them with the existing 90-day allowance for targeted substances.
The medication must be in the traveller’s actual possession or baggage.
When entering Canada, it must be declared to a customs officer at the port of entry.
Except for a limited low-dose codeine exception, the medication must also be in a container obtained from a health-care provider with prescribed information on the label, including the patient or animal’s name, the health-care provider, the drug name, strength and quantity, and the authorized daily dose.
The new rules also allow travellers to carry qualifying prescription medication for an accompanying person or for an accompanying animal for which they are responsible.
Restricted drugs listed in Schedule 4 are not covered by this traveller authorization.
Parallel amendments to the Cannabis Regulations will also allow travellers to carry up to a 90-day supply of prescribed drugs containing cannabis, such as authorized pharmaceutical products, as confirmed in the Regulatory Impact Analysis Statement.
This does not legalize taking other cannabis products or medical cannabis across Canada’s international border.
The Canada Border Services Agency’s general guidance on drugs and travel reminds all travellers that attempting to cross a border with controlled substances without authorization can result in criminal charges, denied entry, or seizure of the medication.
Newcomers to Canada and returning travellers should keep all prescription medication in its original pharmacy-labelled container and carry a copy of the prescription or a letter from their doctor confirming the medical necessity of the medication.
Linked Changes to Cannabis Regulations
The consolidation also triggers amendments to the Cannabis Regulations to maintain consistency between the two legislative frameworks.
Cannabis licence holders and licensed dealers will be required to record the drug identification number for prescription drugs containing cannabis when conducting activities such as import, sale, and distribution.
Pharmacists will also be authorized to distribute drugs containing cannabis to licensed dealers for the purpose of destruction and to other pharmacists for the purpose of filling prescriptions.
Revised responsibilities for master growers under the Cannabis Regulations are also included in the coordinating amendments.
Unified Licensing Framework
The consolidated regulations establish a single licensing framework across all controlled substance categories, replacing the multiple licensing streams that previously existed under separate regulations.
Licensed dealers will operate under harmonized requirements for record-keeping, security, and reporting.
The new framework also introduces updated requirements around licence suspensions and mandatory reporting to Health Canada.
Health Canada is updating forms, web pages, and implementation materials ahead of the new framework.
Pharmacy professionals should also consult their provincial or territorial regulator for jurisdiction-specific guidance.
Key Transition Dates
| Date | What Happens |
|---|---|
| December 17, 2025 | New Controlled Substances Regulations published in the Canada Gazette, Part II |
| October 1, 2026 | Health Canada revokes the six relevant subsection 56(1) class exemptions incorporated into the new framework |
| October 1, 2026 | Consolidated Controlled Substances Regulations come into force |
| October 1, 2026 | Narcotic Control Regulations repealed |
| October 1, 2026 | Benzodiazepines and Other Targeted Substances Regulations repealed |
| October 1, 2026 | Parts G and J of the Food and Drug Regulations are repealed |
| October 1, 2026 | New Classes of Practitioners Regulations repealed |
| October 1, 2026 | Cannabis Regulations amendments take effect |
Provincial Variations Will Shape Real-World Impact
Because Canada’s health-care system divides authority between federal and provincial governments, the practical effect of the October 1 changes will vary depending on where a pharmacist practices.
The federal regulations set the ceiling of what pharmacists and pharmacy technicians are authorized to do with controlled substances.
Provincial and territorial legislation determines which of those federally enabled authorities a pharmacy professional can actually exercise.
Pharmacists in provinces that have broadly empowered their pharmacy professionals will gain immediate access to new authorities like therapeutic substitution on October 1.
Pharmacists in provinces that have not updated their scope-of-practice rules will see no change in what they can do at the dispensing counter, even though the federal framework now permits it.
What Pharmacists and Patients Should Do Before October 1
Pharmacists and health-care practitioners should review the full text of the new Controlled Substances Regulations, published as SOR/2025-242 in the Canada Gazette, to confirm that their current dispensing and prescribing practices align with the consolidated framework.
Pharmacy teams should check with their provincial regulatory college for jurisdiction-specific guidance on which new authorities apply in their province.
Hospital administrators should review the new “person in charge of a hospital” provisions and update internal controlled substance handling protocols as needed.
Patients who take prescription medication containing controlled substances do not need to take any action before October 1.
Their prescriptions remain valid, and the transition should not affect their ability to fill or refill prescriptions at their regular pharmacy.
Travellers planning to enter or leave Canada with prescription medication containing controlled substances around the October 1 transition date should ensure they carry proper documentation, including original labelled containers and a copy of their prescription.
Frequently Asked Questions (FAQs)
Will my current prescription for a controlled substance stop working on October 1?
No, the prescriptions that were valid before October 1 remain valid after October 1. The consolidation reorganizes the regulatory framework behind controlled substance prescriptions but does not change what substances are controlled or invalidate any existing prescriptions.
Can my pharmacist now swap my medication for a different controlled substance?
That depends on where you live. The federal regulations will remove the regulatory barrier to therapeutic substitution beginning October 1, but only pharmacists in provinces or territories that have independently authorized this practice within their scope-of-practice legislation can exercise the authority. Ontario pharmacists, for example, cannot therapeutically substitute one controlled substance for another because the province has not enabled this authority. Ask your pharmacist whether therapeutic substitution is available in your province.
Do the rules for travelling with controlled-substance medication change on October 1?
Yes, travellers will be permitted to carry up to a 90-day supply of prescribed medications containing narcotics, controlled drugs, or targeted substances, subject to the new possession, labelling, and declaration requirements. The rules will also allow qualifying medication to be carried for an accompanying animal.
What is the difference between prescription adaptation and therapeutic substitution?
Prescription adaptation allows a pharmacist to adjust aspects of an existing prescription, including the dose, dosage form, regimen, or route of administration, without changing the medication itself. Therapeutic substitution goes further by allowing the pharmacist to replace the prescribed controlled substance with a different one from the same therapeutic class. Both require appropriate clinical judgment, but therapeutic substitution carries additional provincial authorization requirements under the new consolidated framework.
Are any substances becoming newly controlled because of the October 1 consolidation?
The consolidation itself does not newly control substances that were previously legal. Two synthetic opioids, spirobrorphine and spirochlorphine, will appear in Part 3 of Schedule 4 of the new Controlled Substances Regulations beginning October 1, but both have already been under temporary federal control since June 5, 2026. Their inclusion in the new schedule continues those existing controls.
Fact-Checked: All information in this article has been verified against the Controlled Substances Regulations (SOR/2025-242) as published in the Canada Gazette, Part II, Volume 159, Number 26 on December 17, 2025, the accompanying Regulatory Impact Analysis Statement, Health Canada’s regulatory guidance on controlled substances and precursor chemicals, the Canadian Pharmacists Association’s public statement on therapeutic substitution, the Ontario College of Pharmacists’ implementation guidance on the Controlled Substances Regulations, the Government of Canada’s traveller guidance on prescription medication containing controlled substances, and the Canada Gazette Order amending the Controlled Substances Regulations for spirobrorphine and spirochlorphine (SOR/2026-72).
Disclaimer: This article is for informational purposes only and does not constitute legal, medical, or pharmaceutical advice. Consult a licensed health-care professional or your provincial pharmacy regulatory college for guidance specific to your situation.
Something went wrong. Please refresh the page and/or try again.
You may also like: 3 New CRA Benefit Payments Coming In September 2026
10 New Canada Laws and Rules Taking Effect In September 2026
New Canada Immigration And Refugee Rules Effective September 7
10 New Canada Immigration Changes & Updates In September 2026